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Supplementary Figure S1: Plasmin generation at the cell surface of oncogenic RAS expressing cells. Plasmin generation 
assay by HEK 293 (Figure 2A) or 293T (Figure 2B) cells transduced with empty vector retrovirus (pBabe control), wild type HRAS 
(HRAS WT), oncogenic HRAS GV12 expressing retrovirus (HRASG12V) and oncogenic KRAS G12D (KRASG12D) and stably selected with 
puromycin. Cells were either plated in 96 well plates for two days (HEK 293) before assay or released with enzyme free cell dissociation 





Supplementary Figure S2: RAS activity in RAS expressing HEK 293 cells. HEK 293 cells stably expressing oncogenic HRAS 
G12V (HRASG12V) and oncogenic KRAS G12D (KRASG12D) and empty vector (pBabe control) were plated, lysed and Ras/Raf pull down 
was carried as per the manufacturer’s instructions (Millipore). GTP and GDP loaded empty vector cell lysates were used as positive and 
negative control for the pull down. 
Supplementary Figure S3: Regulation of plasminogen receptor expression by RAS in 293T cells. 293T cells expressing 
empty vector (pBabe control), wild type HRAS (HRAS WT), oncogenic HRAS G12V (HRASG12V) and oncogenic KRAS G12D 
(KRASG12D) were plated, and after three days, lysed and subjected to Western blotting. The membrane was probed with primary antibodies 
as indicated and subsequently probed with IR-dye conjugated secondary antibodies scanned using LI-COR Odyssey scanner. Results are 
presented in triplicate.




doxycycline while plating and were induced every subsequent day. Four days after induction, the cells were lysed in lysis buffer and protein 









vs time2 progress curve (N = 4). Statistical analysis was performed by Student t-test.
Supplementary Figure S5: S100A10 levels in human cancer cell lines. Protein lysates of a panel of well-established human 
cancer cell lines were prepared as described in materials and methods. 20 µg of each protein lysate was subjected to SDS-PAGE, transferred 
onto a nitrocellulose membrane and analyzed by western blotting with the antibodies indicated.






Supplementary Figure S7: Plasminogen receptor expression after knockdown of S100A10.  293T cells stably expressing 
oncogenic HRAS G12V (HRASG12V) and empty vector  (pBabe control) were  transfected with 4 μM of pre-designed siRNA (Ambion) 
specific  for    S100A10  (S100A10  siRNA)  and  a  non-silencing  siRNA  control  (siRNA  control)  using Lipofectamine  2000  transfection 
reagent as per manufacturer’s  instructions (Invitrogen). Cell  lysates were prepared 48 hours after  transfection, and  total  levels of non-
neuronal enolase (ENO1), histone H2B, HMGB-1 were detected by Western blotting.
